Sugi Predict

Sugi Predict / Compounds / SCHEMBL1345151

SCHEMBL1345151

SCHEMBL1345151

CC(=O)N(C)C1CCC(C(=O)O)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.39
▸ PLG P00747 1/20 0.39
▸ PLAT P00750 1/20 0.39
▸ TSHR P16473 2/20 0.38
▸ APLNR P35414 1/20 0.38
▸ GABRP O00591 1/20 0.38
▸ GABRD O14764 1/20 0.38
▸ GABRA1 P14867 1/20 0.38
▸ GABRB1 P18505 1/20 0.38
▸ GABRG2 P18507 1/20 0.38
▸ GABRB3 P28472 1/20 0.38
▸ GABRA5 P31644 1/20 0.38
▸ GABRA3 P34903 1/20 0.38
▸ GABRA2 P47869 1/20 0.38
▸ GABRB2 P47870 1/20 0.38
▸ GABRA4 P48169 1/20 0.38
▸ GABRE P78334 1/20 0.38
▸ PMP22 Q01453 1/20 0.38
▸ GABRA6 Q16445 1/20 0.38
▸ GABRG1 Q8N1C3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2943478 1.00 LMNA (0.39) LMNAPLGPLATTSHRAPLNR
SCHEMBL24131650 1.00 LMNA (0.39) LMNAPLGPLATTSHRAPLNR
SCHEMBL20625308 0.88 ACE (0.36) LMNAPLGPLATTSHRAPLNR
SCHEMBL23389396 0.88 ACE (0.36) LMNAPLGPLATTSHRAPLNR
SCHEMBL5506106 0.86 — —
SCHEMBL12436737 0.84 DPP4 (0.37) TSHRDPP4DPP8DPP9DPP7
SCHEMBL22722026 0.84 DPP4 (0.37) TSHRDPP4DPP8DPP9DPP7
SCHEMBL4969805 0.80 APLNR (0.39) TSHRAPLNRGABRPGABRDGABRA1
SCHEMBL4008610 0.79 LMNA (0.43) LMNAPLGPLATTSHRAPLNR
SCHEMBL14931419 0.79 LMNA (0.43) LMNAPLGPLATTSHRAPLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113801163-B Organic arsenic-based II-type pyruvate kinase inhibitor and preparation method and application thereof 中国科学院上海有机化学研究所 2025-03-04 — — CN disclosed
WO-2021254254-A1 ORGANIC ARSENIC-BASED TYPE II PYRUVATE KINASE INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院上海有机化学研究所 2021-12-23 — — WO disclosed
CN-113801163-A II-type pyruvate kinase inhibitor based on organic arsenic and preparation method and application thereof 中国科学院上海有机化学研究所 2021-12-17 — — CN disclosed
EP-1910362-B1 IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS SIRTRIS PHARMACEUTICALS INC (US) 2012-10-17 — — EP disclosed
EP-1910384-B1 IMIDAZO [2,1-B]THIAZOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS SIRTRIS PHARMACEUTICALS INC (US) 2012-10-10 — — EP disclosed
EP-2468752-A1 Thiazolopyridine derivatives as sirtuin-modulators Sirtris Pharmaceuticals, Inc. (US) 2012-06-27 — — EP disclosed
EP-2388263-A1 Imidazo[2,1-b]thiazole derivatives as sirtuin modulators Sirtris Pharmaceuticals, Inc. (US) 2011-11-23 — — EP disclosed
US-8063075-B2 Pyrrolidine ether derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-11-22 — — US disclosed
EP-2294063-B1 PYRROLIDINE ETHER DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-11-02 — — EP disclosed
EP-2294063-A1 PYRROLIDINE ETHER DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-03-16 — — EP disclosed
US-7375119-B2 Amide type carboxamide derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-05-20 — — US disclosed
CN-100344632-C Fused furan compound TANABE SEIYAKU CO (JP) 2007-10-24 — — CN disclosed
US-20060287329-A1 Amide type carboxamide derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-12-21 — — US disclosed
CN-1860097-A Amide-type carboxamide derivative TANABE SEIYAKU CO (JP) 2006-11-08 — — CN disclosed
EP-1666455-A1 AMIDE TYPE CARBOXAMIDE DERIVATIVE TANABE SEIYAKU CO., LTD. (JP) 2006-06-07 — — EP disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
CN-1723210-A Fused furan compound TANABE SEIYAKU CO (JP) 2006-01-18 — — CN disclosed
US-20050282808-A1 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-22 — — US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP disclosed
EP-1489078-A1 BENZOFURAN DERIVATIVE Tanabe Seiyaku Co., Ltd. (JP) 2004-12-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282808-A1 Benzofuran derivative F12, F2, F11 LMNA 3104/4885PLG 436/4885PLAT 89/4885
US-20060287329-A1 Amide type carboxamide derivative F12, F11, F13A1 LMNA 1114/4885PLG 1029/4885PLAT 455/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 LMNA 1796/4885PLG 125/4885PLAT 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.